1: Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin Daniel W. Bougie, Mark Rasmussen, Jieqing Zhu, Richard H. Aster Blood. 2012 Jun 28; 119(26): 6317–6325. Prepublished online 2012 Apr 6. doi: 10.1182/blood-2012-01-406322 PMCID: PMC3383197
2: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban Shaker A Mousa, Jeffrey M Bozarth, Ulhas P Naik, Andrew Slee Br J Pharmacol. 2001 Jun; 133(3): 331–336. doi: 10.1038/sj.bjp.0703943 PMCID: PMC1572788
3: Lymphocyte Adhesion to Candida albicans Christopher B. Forsyth, Herbert L. Mathews Infect Immun. 2002 Feb; 70(2): 517–527. doi: 10.1128/IAI.70.2.517-527.2002 PMCID: PMC127679
4: Pharmacological inhibition of β3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity Ashley Browne, Laura A. Tookman, Carin K. Ingemarsdotter, Russell D. Bouwman, Katrina Pirlo, Yaohe Wang, Iain A. McNeish, Michelle Lockley Cancer Res. Author manuscript; available in PMC 2016 Jan 15.Published in final edited form as: Cancer Res. 2015 Jul 15; 75(14): 2811–2821. Published online 2015 May 14. doi: 10.1158/0008-5472.CAN-14-3761 PMCID: PMC4506788
5: Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer Andrew R. Reynolds Dose Response. 2010; 8(3): 253–284. Published online 2010 Apr 23. doi: 10.2203/dose-response.09-049.Reynolds PMCID: PMC2939687
6: The use of synthetic analogues of Arg-Gly-Asp (RGD) and soluble receptor of tumor necrosis factor to prevent acute and chronic experimental liver injury. R. Bruck, R. Hershkoviz, O. Lider, H. Shirin, H. Aeed, Z. Halpern Yale J Biol Med. 1997 Jul-Aug; 70(4): 391–402.PMCID: PMC2589337
7: αvβ3 Integrin Limits the Contribution of Neuropilin-1 to Vascular Endothelial Growth Factor-induced Angiogenesis Stephen D. Robinson, Louise E. Reynolds, Vassiliki Kostourou, Andrew R. Reynolds, Rita Graça da Silva, Bernardo Tavora, Marianne Baker, John F. Marshall, Kairbaan M. Hodivala-Dilke J Biol Chem. 2009 Dec 4; 284(49): 33966–33981. Published online 2009 Oct 16. doi: 10.1074/jbc.M109.030700 PMCID: PMC2797167
8: A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. V. W. Engleman, G. A. Nickols, F. P. Ross, M. A. Horton, D. W. Griggs, S. L. Settle, P. G. Ruminski, S. L. Teitelbaum J Clin Invest. 1997 May 1; 99(9): 2284–2292. doi: 10.1172/JCI119404 PMCID: PMC508061
9: Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators Alessandra Tolomelli, Paola Galletti, Monica Baiula, Daria Giacomini Cancers (Basel) 2017 Jul; 9(7): 78. Published online 2017 Jul 5. doi: 10.3390/cancers9070078 PMCID: PMC5532614
10: Anti-thrombotic agents derived from snake venom proteins Tur-Fu Huang, Chun-Chieh Hsu, Yu-Ju Kuo Thromb J. 2016; 14(Suppl 1): 18. Published online 2016 Oct 4. doi: 10.1186/s12959-016-0113-1 PMCID: PMC5056499
11: Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors Nilgun Isik Reed, You-Zhi Tang, Joel McIntosh, Yibing Wu, Kathleen S. Molnar, Annafelicia Civitavecchia, Dean Sheppard, William F. DeGrado, Hyunil Jo ACS Med Chem Lett. 2016 Oct 13; 7(10): 902–907. Published online 2016 Aug 30. doi: 10.1021/acsmedchemlett.6b00196 PMCID: PMC5066160